Supernus Pharmaceuticals Files 8-K on Financials
Ticker: SUPN · Form: 8-K · Filed: 2025-02-11T00:00:00.000Z
Sentiment: neutral
Topics: financial-reporting, sec-filing
Related Tickers: SUPN
TL;DR
SUPN filed an 8-K on Feb 11, 2025, covering financial results and condition.
AI Summary
On February 11, 2025, Supernus Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or significant events were detailed in the provided text.
Why It Matters
This filing indicates Supernus Pharmaceuticals is providing updates on its financial performance and condition to the SEC, which is important for investors to monitor the company's health.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of financial information and does not indicate any immediate or significant risks.
Key Players & Entities
- Supernus Pharmaceuticals, Inc. (company) — Registrant
- February 11, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Rockville, MD (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing by Supernus Pharmaceuticals, Inc.?
The primary purpose of this 8-K filing is to report on the company's Results of Operations and Financial Condition, as well as to provide Financial Statements and Exhibits.
On what date was the earliest event reported in this filing?
The earliest event reported in this filing was on February 11, 2025.
In which state was Supernus Pharmaceuticals, Inc. incorporated?
Supernus Pharmaceuticals, Inc. was incorporated in Delaware.
What is the address of Supernus Pharmaceuticals, Inc.'s Principal Executive Offices?
The address of Supernus Pharmaceuticals, Inc.'s Principal Executive Offices is 9715 Key West Ave, Rockville, MD 20850.
What is the SEC file number for Supernus Pharmaceuticals, Inc.?
The SEC file number for Supernus Pharmaceuticals, Inc. is 001-35518.
Filing Stats: 497 words · 2 min read · ~2 pages · Grade level 9.2 · Accepted 2025-02-11 17:13:21
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share SUPN The Nasdaq Sto
Filing Documents
- supn-20250211.htm (8-K) — 27KB
- ex-991xearningscallannounc.htm (EX-99.1) — 8KB
- image_0a.jpg (GRAPHIC) — 5KB
- 0001356576-25-000006.txt ( ) — 165KB
- supn-20250211.xsd (EX-101.SCH) — 2KB
- supn-20250211_lab.xml (EX-101.LAB) — 21KB
- supn-20250211_pre.xml (EX-101.PRE) — 12KB
- supn-20250211_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On February 11, 2025, Supernus Pharmaceuticals, Inc. issued a press release announcing that it expects to report its business results for the fourth quarter and full year of 2024 after the market closes on Tuesday, February 25, 2025. The Company will host a conference call and webcast on Tuesday, February 25, 2025 at 4:30 p.m. E.T. to discuss its fourth quarter and full year 2024 financial and business results. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Description 99.1 Press Release dated February 11, 2025 filed as an Exhibit pursuant to Item 2.02 hereof. 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL. 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SUPERNUS PHARMACEUTICALS, INC. DATED: February 11, 2025 By: /s/ Timothy C. Dec Timothy C. Dec Senior Vice President and Chief Financial Officer 3